Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 15;13(22):6883.
doi: 10.3390/jcm13226883.

Monoclonal Antibody Switching in Biologic Treatment of Chronic Rhinosinusitis with Nasal Polyps

Michael Habenbacher  1 , Ulrich Moser  1 , Oliver Hadl  1 , Peter Kiss  1 , Clemens Holzmeister  1 , Jakob Pock  1 , Katharina Walla  1 , Angelika Lang  1 , Alexandros Andrianakis  1
Affiliations

Monoclonal Antibody Switching in Biologic Treatment of Chronic Rhinosinusitis with Nasal Polyps

Michael Habenbacher et al. J Clin Med. .

Abstract

Objectives: to evaluate our real-world data on the efficacy and safety of switching between two monoclonal antibodies in biologic treatment of uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Methods: All patients receiving biologic treatment for uncontrolled CRSwNP between April 2020 and March 2024 at a tertiary referral center who needed transitioning between biologic agents were retrospectively analyzed. The following parameters were investigated: patient's clinical characteristics, wash-out periods, treatment outcome, and switching-related side effects. Results: Out of 91 CRSwNP patients who received biologic treatment, 4 patients (4.4%) necessitated switching to an alternative biologic agent. Three patients were switched to a different antibody because of insufficient symptom control with the initially prescribed biologic, while the other patient required switching to an alternative agent due to a side effect. Switching resulted in all four patients achieving a significant improvement in all outcome parameters. There were no switching-related side effects, and the switching procedure was performed in three cases without a wash-out period. Conclusion: CRSwNP patients under biologic therapy with an insufficient response or medication-related side effect may benefit from switching to an alternative biologic agent. Larger, prospective multicenter studies are warranted to further validate the effectiveness and safety of switching agents in the biologic treatment of CRSwNP.

Keywords: CRSwNP; biologics; chronic rhinosinusitis; dupilumab; mepolizumab; omalizumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Fokkens W.J., Lund V.J., Hopkins C., Hellings P.W., Kern R., Reitsma S., Toppila-Salmi S., Bernal-Sprekelsen M. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58((Suppl. S29)):1–464. doi: 10.4193/Rhin20.401. - DOI - PubMed
    1. Johansson L., Akerlund A., Holmberg K., Melén I., Bende M. Prevalence of nasal polyps in adults: The Skövde population-based study. Ann. Otol. Rhinol. Laryngol. 2003;112:625–629. doi: 10.1177/000348940311200709. - DOI - PubMed
    1. Jankowski R., Bouchoua F., Coffinet L., Vignaud J.M. Clinical factors influencing the eosinophil infiltration of nasal polyps. Rhinology. 2002;40:173–178. - PubMed
    1. Kowalski M.L., Agache I., Bavbek S., Bakirtas A., Blanca M., Bochenek G., Bonini M., Heffler E., Klimek L., Laidlaw T.M., et al. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. Allergy. 2019;74:28–39. doi: 10.1111/all.13599. - DOI - PubMed
    1. Brkic F.F., Liu D.T., Klimbacher R., Campion N.J., Bartosik T.J., Vyskocil E., Stanek V., Tu A., Arnoldner T., Bangert C., et al. Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD. Rhinology. 2023;61:320–327. doi: 10.4193/Rhin22.408. - DOI - PubMed

LinkOut - more resources